Comprehensive Overview

The Group is an innovative platform for genetic testing solutions for assisted reproduction in China. Its PGT-A kit can screen for aneuploids in embryos before implantation. It is the first and only third-generation in vitro infant genetic testing kit approved by the National Drug Administration. The group is currently developing two more pre-implantation genetic testing (PGT) products. It is expected that the relevant kits will be registered and approved by the National Drug Administration in 2022 and 2024 respectively, which will help strengthen the Group's leading position in the Chinese third-generation IVF genetic testing kit market and take the lead in potential competition.

Risk Factors

Most of the Group's current revenue comes from the sale of two types of products, namely the self-developed PGT-A reagent kit and the resale NIPT kit. The demand, sales value, and profit margin of these products cannot be guaranteed. Also, if the group is unable to maintain relationships with key business partners, or to establish or seek more cooperation and strategic alliances, business performance and prospects may be adversely affected. The Group's product development also involved a large amount of capital expenditure. During the historical record period, the net loss recorded by the Group was partly due to operating costs. It is anticipated that operating costs will continue to be produced and increased in the foreseeable future.